The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Open accessAbstract
SUMMARY Aberrant expression of programmed death ligand-1 (PD-L1) in tumor cells promotes cancer progression by suppressing cancer immunity. The retinoblastoma protein RB is a tumor suppressor known to regulate the cell cycle, DNA damage response, and differentiation. Here, we demonstrate that RB interacts with nuclear factor κB (NF-κB) protein p65 and that their interaction is primarily dependent on CDK4/6-mediated serine-249/threonine-252 (S249/T252) phosphorylation of RB. RNA-seq analysis shows a subset of NF-κB pathway genes including PD-L1 are selectively upregulated by RB knockdown or CDK4/6 inhibitor. S249/T252-phosphorylated RB inversely correlates with PD-L1 expression in patient samples. Expression of a RB-derived S249/T252 phosphorylation-mimetic peptide suppresses radiotherapy-induced upregulation of PD-L1 and augments therapeutic efficacy of radiation in vivo. Our findings reveal a previously unrecognized tumor suppressor function of hyperphosphorylated RB in suppressing NF-κB activity and PD-L1 expression and suggest that the RB-NF-κB axis can be exploited to overcome cancer immune evasion triggered by conventional or targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Self-citationCyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90507-2 · Cited by 897
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
Goodrich, D. W., Wang, N. P., Qian, Y.-W., Lee, E. Y.-H. P., & Lee, W.-H. (1991) · Cell · doi:10.1016/0092-8674(91)90181-w · Cited by 707
Self-citationEradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases
Zarkowska, T., & Mittnacht, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12738 · Cited by 493
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
LeRoy, G., Rickards, B., & Flint, S. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.01.018 · Cited by 372
Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N., & Narayan, P. (1995) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/bf02631333 · Cited by 340
Zhang, P., Wang, D., Zhao, Y., Ren, S., Gao, K., Ye, Z., Wang, S., Pan, C.-W., Zhu, Y., Yan, Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4379 · Cited by 297
Self-citationThe Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C., Wang, K., Mo, F., Haegert, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.012 · Cited by 279
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Gevensleben, H., Dietrich, D., Golletz, C., Steiner, S., Jung, M., Thiesler, T., Majores, M., Stein, J., Uhl, B., Müller, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2042 · Cited by 235
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Zhao, D., Lu, X., Wang, G., Lan, Z., Liao, W., Li, J., Liang, X., Chen, J. R., Shah, S., Shang, X., et al. (2017) · Nature · doi:10.1038/nature21357 · Cited by 218
Ariga, A., Namekawa, J.-I., Matsumoto, N., Inoue, J.-I., & Umezawa, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112063200 · Cited by 206
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 172
Self-citationAn RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences
Ishak, C. A., Marshall, A. E., Passos, D. T., White, C. R., Kim, S. J., Cecchini, M. J., Ferwati, S., MacDonald, W. A., Howlett, C. J., Welch, I. D., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.021 · Cited by 167
RB: mitotic implications of a tumour suppressor
Manning, A. L., & Dyson, N. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3216 · Cited by 161
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Self-citationBurke, J. R., Deshong, A. J., Pelton, J. G., & Rubin, S. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.108167 · Cited by 148
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H. N., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D. O., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 129
Gubern, A., Joaquin, M., Marqués, M., Maseres, P., Garcı́a-Garcı́a, J., Amat, R., González-Nuñez, D., Oliva, B., Real, F. X., de Nadal, E., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.015 · Cited by 96
Hassler, M., Singh, S., Yue, W. W., Luczynski, M. T., Lakbir, R., Sánchez‐Sánchez, F., Bader, T., Pearl, L. H., & Mittnacht, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.023 · Cited by 81
Massari, F., Ciccarese, C., Caliò, A., Munari, E., Cima, L., Porcaro, A. B., Novella, G., Artibani, W., Sava, T., Eccher, A., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0396-3 · Cited by 69
E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo
Sun, H., Wang, Y., Chinnam, M., Zhang, X., Hayward, S. W., Foster, B. A., Nikitin, A. Y., Wills, M. L., & Goodrich, D. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015027108 · Cited by 41
Self-citationOscillation dynamics underlie functional switching of NF-κB for B-cell activation
Inoue, K., Shinohara, H., Behar, M., Yumoto, N., Tanaka, G., Hoffmann, A., Aihara, K., & Okada, M. (2016) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.24 · Cited by 40
Day, K. C., McCabe, M. T., Zhao, X., Wang, Y. Z., Davis, J. N., Phillips, J. L., von Geldern, M., Ried, T., KuKuruga, M. A., Cunha, G. R., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205361200 · Cited by 33
Cited by
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
The p38 Pathway: From Biology to Cancer Therapy
Martínez-Limón, A., Joaquin, M., Caballero, M., Posas, F., & de Nadal, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061913 · Cited by 411
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Metadata
- Authors
- Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., Kohli, M., Jimenez, R., Wang, L., Goodrich, D. W., de Bono, J., Dong, H., Wu, H., Zhu, R., & Huang, H.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 73
- Issue
- 1
- Pages
- 22-35.e6
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2901997433
- Cited by
- 257
- References
- 46
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.